Alert icon
We're changing our privacy policy. This stuff matters.  Learn more  Dismiss

Abbott Labs Tops Q4 Estimates, Announced 1,900 Job Cuts (ABT)

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
237 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Jan 26, 2011

Abbott Labs (NYSE:ABT) reported Q4 EPS of $1.30, a penny above the consensus estimate of $1.29 per share. Revenue rose 13.4% to $9.97 billion, above the Street estimate of $9.89 billion. Sales of Humira rose 13% to $1.88 billion.

The company said it sees ongoing full-year 2011 EPS rising double digits over 2010. This equates to a range of $4.54-$4.64, vs. estimates of $4.63. Abbott said its 2011 outlook reflects the incremental impact of costs associated with U.S. Healthcare Reform, as well as the impact of European austerity measures.

Chairman and CEO Miles White said, "Despite a very challenging environment, 2010 was another productive year for Abbott, resulting in strong financial performance. We also took decisive long-term strategic actions to expand our emerging markets presence and late-stage pipeline to better position Abbott for sustainable long-term growth. We anticipate delivering another year of double-digit ongoing earnings-per-share growth in 2011."

Abbott also said that it would be streamlining its U.S. pharmaceutical operations which would result in 1,900 job cuts representing 2% of its total workforce.

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more